GlassScriptPhysician profile
Eric A Tungol
NPI 1912384058
$8,138.83
in general payments reported to CMS, 2019-2025
12 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $949 · 2022: $844 · 2023: $5,307 · 2024: $649 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,380 · Travel and Lodging: $1,029 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,693.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,380.00 |
| Travel and Lodging | $1,029.05 |
| Education | $243.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $4,912.71 | 2021-2025 | |
| Harmony Biosciences LLC | $1,458.70 | 2021-2025 | Wakix |
| Axsome Therapeutics, INC. | $427.00 | 2022-2025 | Sunosi |
| Idorsia Pharmaceuticals US INC | $345.04 | 2022-2024 | Quviviq |
| Zoll Respicardia, INC. | $308.79 | 2021 | |
| Merz North America, INC. | $165.87 | 2023 | Xeomin |
| Avadel Cns Pharmaceuticals, LLC | $134.25 | 2023-2025 | Lumryz |
| Vanda Pharmaceuticals INC. | $127.24 | 2022-2023 | Hetlioz |
| Merck Sharp & Dohme LLC | $112.86 | 2022-2023 | Belsomra, Verquvo |
| Eisai INC. | $60.36 | 2021-2022 | |
| Resmed Corp | $51.71 | 2021-2023 | |
| Inspire Medical Systems, INC. | $34.30 | 2023-2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tungol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.